Infectious Disease · Medical Literature
[Comment] China lists severe fever with thrombocytopenia syndrome as a notifiable disease: a crucial step forward
Abstract
Severe fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV, family Phenuiviridae), is a viral haemorrhagic fever with a case-fatality rate (CFR) exceeding 10%.1 First identified in central China in 2009, SFTSV now has the broadest geographical distribution among known tick-borne viruses in Asia and has been listed by WHO as a priority pathogen.2 After 16 years, China has designated SFTS as a notifiable Class B disease,3 a landmark decision that elevates SFTS to the same legal status as dengue, malaria, and Japanese encephalitis, with far-reaching implications for surveillance, clinical management, and research.
Clinical relevance
What are the public health, surveillance, clinical management, and research implications of China's designation of severe fever with thrombocytopenia syndrome (SFTS) as a notifiable Class B infectious disease, 16 years after the pathogen's initial identification? __SNAPSHOT__ {"studyDesign":"Expert commentary / policy analysis (published as a Comment in The Lancet Microbe; not an original research study — no primary data collected)","setting":"China (national policy context); authors affiliated with the State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, and the Department of Infectious Diseases, First Affiliated Hospital of Nanjing Medical University, Nanjing, China","sampleSize":"Not applicable — no patient-level data analyzed","population":"Persons at risk for SFTS in China and broader Asia; the disease disproportionately affects rural-dwelling farmers and older adults in endemic mountainous and forested regions","intervention":"China's legislative reclassification of SFTS as a notifiable Class B infectious disease under China's Infectious Disease Law, requiring mandatory reporting (typically within 24 hours) through the National Notifiable Disease Report System","comparator":"Prior non-notifiable status of SFTS in China; comparators referenced include Japan and South Korea, where mandatory notifiable disease systems for SFTS are already established","primaryOutcome":"No quantitative primary outcome — the commentary evaluates the expected downstream effects on surveillance completeness, case fatality rate accuracy, government resource allocation, outbreak detection, and research prioritization","followUp":"Not applicable","fundingSource":"Not reported"}
Key findings
This is a policy commentary, not an interventional or observational study; no new primary efficacy or safety data are presented. The authors highlight several key epidemiological facts grounding the policy change: (1) SFTS, caused by SFTSV (family Phenuiviridae), carries a CFR exceeding 10% in published series, with endemic hospital data documenting a true CFR of 10–30%, far above figures captured by voluntary national reporting. (2) SFTSV was first identified in central China in 2009 and now holds the broadest geographical distribution among known tick-borne viruses in Asia, with China reporting more than 20,000 cumulative cases by 2023. (3) Epidemiological surveillance data from 2010–2018 documented a CFR of 10.5% (95% CI: 9.8–11.2%) among 7,721 laboratory-confirmed cases, with annual incidence increasing more than 20-fold and endemic townships expanding from 27 to 1,574 over the same period — underscoring the inadequacy of passive surveillance. (4) The absence of mandatory reporting was identified as a structural driver of severe underestimation of true CFR, as fatal cases in rural areas without definitive diagnosis were not systematically captured. (5) Comparison with Japan (CFR ~27%) and South Korea (CFR ~32.6%) — both of which operate mandatory notifiable disease systems — highlights the data gap created by China's previously voluntary reporting approach. No NNT, NNH, relative risk, or odds ratio data are reported or calculable from this commentary.
Practice implications
This commentary establishes that China's Class B notifiable disease designation for SFTS is a landmark regulatory step with substantial anticipated public health consequences. By mandating reporting from every health care institution — including village clinics and county hospitals — to the National Notifiable Disease Report System, the policy creates the infrastructure for a real-time nationwide case registry enabling early outbreak detection, spatiotemporal tracking, and intervention evaluation. It also unlocks dedicated government funding for surveillance infrastructure, diagnostics, and vector control. Critically, the policy is expected to correct a long-standing and severe underestimation of the true disease burden and CFR. The findings of this commentary apply to all clinicians and public health practitioners managing or surveilling SFTS in China and in other Asian countries where the disease is emerging. The commentary does not address what this policy change will mean for individual patient management protocols, treatment algorithms, or therapeutic outcomes. Patients outside China, in Japan and South Korea (where mandatory reporting already exists), are not the primary subject, though the comparative framing is instructive. IMPORTANT LIMITATION: Only the published abstract was available for review; full-text access to the complete commentary, including all cited primary data and the authors' full argumentation, was not available. Clinicians should consult the complete Lancet Microbe article (DOI: 10.1016/S2666-5247(26)00095-9) before applying the policy framing to specific institutional or clinical decisions. __LIMITATIONS__ 1. Study type: This is an expert commentary — the lowest tier of evidence. It does not present original data and cannot demonstrate causality or quantify the impact of the policy change. 2. Projection without outcome data: The anticipated benefits of notifiable status (improved surveillance completeness, accurate CFR estimation, funding allocation) are logical inferences, not empirically demonstrated outcomes. 3. Selective citation: As with all commentaries, the authors may selectively reference studies that support their argument; independent critical appraisal of the cited literature is not possible from the abstract alone. 4. Generalizability: The regulatory and health system infrastructure in China is specific; lessons for other low- and middle-income settings with different legal frameworks may not be directly transferable. 5. No therapeutic or clinical management data: The commentary does not address whether notifiable status will change individual clinical management, treatment access, or patient outcomes at the point of care. 6. Absence of cost-effectiveness analysis: The resource implications of expanded surveillance and mandatory reporting infrastructure are not quantified. 7. Non-vector-borne transmission risk acknowledged but not quantified: Emerging evidence of human-to-human and animal-to-human (non-tick) transmission routes is noted, but their epidemiological contribution to overall burden remains incompletely characterized. 8. Abstract-only review: Full-text details of methods, cited evidence, and nuanced policy arguments were not accessible for this summary. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ China's designation of SFTS as a notifiable Class B disease — 16 years after the pathogen's identification — mandates universal case reporting, closes a critical surveillance gap that had systematically underestimated disease burden and case fatality, and aligns China with Japan and South Korea's established reporting frameworks. Clinicians practicing in SFTS-endemic regions should anticipate expanded reporting requirements, improved epidemiological data quality, and potential increases in government-supported diagnostic and vector control resources. No change to individual patient management protocols is directly specified by this policy commentary, and evidence-based treatment remains supportive in the absence of licensed antivirals or vaccines.